Original Articles

Effects of topical Polymyxin Neomycin Hydrocortison in Patients with Non-Allergic Rhinitis, a randomized clinical trial.

Polymyxin Neomycin for Non-Allergic Rhinitis

Abstract

Background and aims: Bacterial infection is involved in the pathogenesis of inflammatory non-allergic rhinitis (NAR), and a broad-spectrum antibiotic should reduce the severity of the disease by eliminating the mucosal biofilm. The purpose of this study is to assess the efficacy of a topical mixture of polymyxin, neomycin, and hydrocortisone in patients with NAR
Materials and Methods: This double-blind phase 3 randomized clinical trial was conducted on 90 patients with non-allergic rhinitis (NAR) in Mashhad, Iran. The subjects experienced symptoms for more than two weeks, and the pretrial course of topical corticosteroids was ineffective. Patients were randomly assigned to treatment groups receiving polymyxin NH, hydrocortisone, or saline. The drug was administered as nasal drops three times daily for a treatment course of two weeks, and the containers were identical. The primary outcome was nasal obstruction.
Results: The pretrial comparison showed no significant difference between groups in terms of clinical findings. However, after the trial, nasal obstruction, as the primary outcome, significantly decreased from 20 subjects (66%) to 7 subjects (23%) in the Polymyxin NH group, along with other secondary outcomes, including palatal itching (56% to 23%), sneezing (76% to 40%), mucosal inflammation (100% to 75%), post-nasal drip (PND) (96% to 63%), and concha swelling (96% to 73%). In the other groups, sneezing was the only significant improvement observed in the saline group. Cytology of nasal discharge showed a reduction in nasal neutrophil counts in the Polymyxin NH group (68±16.7% to 46±27.6%) compared to the hydrocortisone and saline-treated groups. Conclusions: Topical intranasal polymyxin NH is effective in treating patients with non-allergic rhinitis.

1. Meng Y, Wang C, Zhang L. Diagnosis and treatment of non-allergic rhinitis: focus on immunologic mechanisms. Expert Rev Clin Immunol 2021;17(1):51-62.
2. De Corso E, Seccia V, Ottaviano G, et al. Clinical evidence of type 2 inflammation in non-allergic rhinitis with eosinophilia syndrome: a systematic review. Curr Allergy Asthma Rep 2022;1-14.
3. Van Gerven L, Boeckxstaens G, Hellings P. Up-date on neuro-immune mechanisms involved in allergic and non-allergic rhinitis. Rhinology 2012; 50(3):227-35.
4. Hellings PW, Klimek L, Cingi C, et al. Non‐allergic rhinitis: position paper of the European Academy of Allergy and Clinical Immunology. Allergy 2017; 72(11):1657-65.
5. Del Giudice AM, Barbara M, Russo GM, et al. Cell-mediated non-allergic rhinitis in children. Intl J Ped Otorhinolaryngol 2012; 76(12):1741-5.
6. Ellis AK, Keith PK. Nonallergic rhinitis with eosinophilia syndrome. Cur allergy Asthma Rep 2006; 6(3):215-20.
7. Dykewicz MS, Wallace DV, Amrol DJ, et al. Rhinitis 2020: a practice parameter update. J Allergy Clin Immunol 2020; 146(4):721-67.
8. Bousquet J, Fokkens W, Burney P, et al. Important research questions in allergy and related diseases: nonallergic rhinitis: a GA2LEN paper. Allergy 2008; 63(7):842-53.
9. Cole AL, Muthukrishnan G, Chong C, et al. Host innate inflammatory factors and staphylococcal protein A influence the duration of human Staphylococcus aureus nasal carriage. Muc Immunol 2016; 9(6):1537-48.
10. Delemarre T, Bochner BS, Simon HU, et al. Neutrophils and eosinophils in chronic rhinosinusitis. J allergy Clin Immunol 2021; 148(2):327-35.
11. Fokkens WJ, Lund VJ, Hopkins C, et al. European position paper on rhinosinusitis and nasal polyps 2020. Rhinology. 2020 Feb 20;58(Suppl S29):1-464. doi: 10.4193/Rhin20.600. PMID: 32077450.
12. Amani S, Moeini M. Comparison of boric acid and combination drug of polymyxin, neomycin and hydrocortisone (polymyxin NH) in the treatment of acute otitis externa. J Clin Dia Res 2016; 10(7):MC01.
13. Association WM. World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. Jama 2013; 310(20):2191-4.
14. Doyle WJ, Gentile DA, Skoner DP. Viral and bacterial rhinitis. Clin Allergy Immunol 2007; 19:177-95.
15. Erhan E, Külahli I, Kandemir O, et al Comparison of topical silver nitrate and flunisolide treatment in patients with idiopathic non-allergic rhinitis. Tokai J Exp Clin Med 1996; 21(2):103-11.
16. Shah R, McGrath KG, editors. Nonallergic rhinitis. Allergy and Asthma Proceedings; 2012: OceanSide Publications.
17. Sykes D, Chan K, Wilson R, et al. Relative importance of antibiotic and improved clearance in topical treatment of chronic mucopurulent rhinosinusitis: a controlled study. Lancet 1986; 328(8503):359-60.
18. Desrosiers MY, Salas-Prato M. Treatment of chronic rhinosinusitis refractory to other treatments with topical antibiotic therapy delivered by means of a large-particle nebulizer: results of a controlled trial. Otolaryngol 2001; 125(3):265-9.
19. Barazi R, Bawab I, Dunia G, et al. The Use of Topical Intranasal Antibiotics in Pediatric Chronic Rhinosinusitis. Ann Otolaryngol Rhinol 2016; 3(12):1150.
20. Mao T, Kim J, Peña-Hernández MA, et al; Yale SARS-CoV-2 Genomic Surveillance Initiative; Gopinath S, Wilen CB, Palm N, Dela Cruz CS, Iwasaki A. Intranasal neomycin evokes broad-spectrum antiviral immunity in the upper respiratory tract. Proc Natl Acad Sci 2024; 121(18):e2319566121.
Files
IssueVol 12 No 4 (2024) QRcode
SectionOriginal Articles
DOI https://doi.org/10.18502/jmb.v12i4.17007
Keywords
Bacterial biofilm Hydrocortisone Nasal Neutrophils Neomycin Non-Allergic Rhinitis Polymyxin.
Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
How to Cite
1.
Mirsadraee M, Mollazadeh S, Ghiyasimoghaddam N. Effects of topical Polymyxin Neomycin Hydrocortison in Patients with Non-Allergic Rhinitis, a randomized clinical trial. J Med Bacteriol. 2024;12(4):55-64.